Teva and Amgen Settle Over Kidney Disease Patent Infringement
Teva Pharmaceutical shares made a handy gain on Thursday after it was announced that the firm has settled with Amgen for its treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA | TEVA Price Prediction) announced on Thursday that it has settled with Amgen Inc. (NASDAQ: AMGN) for its treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.
The ongoing dispute regarding Teva’s generic cinacalcet HCI product is officially over. Teva and Amgen have been involved in patent infringement litigation, and Teva recently received approval for and launched its generic product in the United States.
According to the settlement, the litigation between the parties will be ended and Teva has agreed to stop selling its generic product until its license date in mid-year 2021, or earlier under certain circumstances.
Also, Teva will pay Amgen an undisclosed amount as part of the settlement. That amount and other terms of the settlement are confidential.
For some quick background: Cinacalcet is a calcium-sensing receptor agonist indicated for secondary HPT in adult patients with CKD on dialysis. It is also used for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.
Shares of Teva were last seen up about 6% at $16.77, in a 52-week range of $14.59 to $25.96. The stock has a consensus analyst price target of $22.94.
Amgen was down nearly 1% at $190.42 a share, with a consensus price target of $204.52. The 52-week trading range is $163.31 to $210.19.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
